Sachiyo Minegishi
No más puestos en curso
Perfil
Sachiyo Minegishi worked as a Senior Director at Aegerion Pharmaceuticals, Inc. from 2012 to 2016, and as a Vice President at bluebird bio, Inc. from 2016 to 2020.
She also worked as the Head of Finance at Akouos, Inc. Ms. Minegishi completed her undergraduate degree at the Massachusetts Institute of Technology and earned an MBA from The Wharton School of the University of Pennsylvania.
Antiguos cargos conocidos de Sachiyo Minegishi.
| Empresas | Cargo | Fin |
|---|---|---|
| BLUEBIRD BIO, INC. | Corporate Officer/Principal | 01/09/2020 |
| AEGERION PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/04/2016 |
| AKOUOS | Director of Finance/CFO | - |
Formación de Sachiyo Minegishi.
| Massachusetts Institute of Technology | Undergraduate Degree |
| The Wharton School of the University of Pennsylvania | Masters Business Admin |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| BLUEBIRD BIO, INC. | Health Technology |
| Empresas privadas | 2 |
|---|---|
Aegerion Pharmaceuticals, Inc.
 Aegerion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aegerion Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in the development and commercialization of therapies for patients with debilitating rare diseases. The company was founded by David I. Scheer, Gerald L. Wisler and William H. Lewis in 2005 and is headquartered in Cambridge, MA. | Health Technology |
Akouos, Inc.
 Akouos, Inc. BiotechnologyHealth Technology Akouos, Inc. is a precision genetic medicine company, which engages in the development of precision genetic medicines to restore and preserve hearing in genetically-defined patient populations. The firm's lead product candidate, AK-OTOF, is a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene. It develops targeted adeno-associated viral vector based gene therapies for sensorineural hearing loss, which results from dysfunction or damage to sensory cells and nerve fibers of the inner ear. The company was founded by Emmanuel J. Simons, William F. Sewell, Richard H. Smith, Luk H. Vandenberghe, and Michael J. McKenna on March 7, 2016 and is headquartered in Boston, MA. | Health Technology |
- Bolsa de valores
- Insiders
- Sachiyo Minegishi
